Gilead Sciences 8-K 2007
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 10, 2007
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA
(Address of principal executive offices)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
SECTION 1 REGISTRANTS BUSINESS AND OPERATIONS
On May 10, 2007, Gilead Sciences Limited (GSL), one of the wholly-owned Irish subsidiaries of Gilead Sciences, Inc., a Delaware corporation (the Company), entered into an Addendum to Tenofovir Disoproxil Fumarate Manufacturing Supply Agreement (the Addendum) with PharmaChem Technologies (Grand Bahama) Ltd. (PharmaChem). The Addendum amends that certain Tenofovir Disoproxil Fumarate Manufacturing Supply Agreement by and between Gilead World Markets, Ltd. (GWM) and PharmaChem dated July 17, 2003 (the Original Agreement, and as amended, the Agreement). A novation was entered into by and among GWM, GSL and PharmaChem on June 14, 2004, to substitute GSL for GWM as a party to the Original Agreement.
Under the terms of the Addendum, GSL will be obligated to purchase certain minimum quantities of bulk tenofovir disoproxil fumarate, which is an active pharmaceutical ingredient in Truvada® (emtricitabine and tenofovir disoproxil fumarate), Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Viread® (tenofovir disoproxil fumarate), from PharmaChem through 2010, unless the Agreement is earlier terminated. The Addendum also provided for the purchase by PharmaChem of certain key raw materials required for the manufacturing of tenofovir disoproxil fumarate from GSL.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 7, 2007